Clinical Evaluation of Chronic Hepatitis C and Indications for HCV Treatment
Abstract
Keywords
Full Text:
PDFReferences
Williams R. Global challenges in liver disease. Hepatology. 2006;44(3):521-526.
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 Suppl 1):S30-S34.
Backus LI, Belperio PS, Loomis TP, et al. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med. 2013;173(16):1549-1552.
Leigh JP, Bowlus CL, Leistikow BN, et al. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231-2237.
Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17-24.
Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9(3):383-998.
Alter MJ, Seeff LB, Bacon BR, et al. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141(9):715-717.
Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334(26):1685-1690.
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(1):1-39.
Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880-1889.
Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817-822.
Chou R, Clark EC, Helfand M, et al. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(6):465-479.
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509 –516.e1.
Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–844.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36 (5 Suppl 1):S35-S46.
Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):
-1058.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis pro-gression in patients with chronic hepatitis C. The OBSVIRC, META-VIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832.
Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med. 2001;134(2):120-124.
Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42(1):5-13.
Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43(2 Suppl 1):S113-S120.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):2589-2600.
Pérez-Álvarez R, García-Samaniego J, Solá R, et al. Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev Esp Enferm Dig. 2012;104(1):21-28.
Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80.
Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17(3):201-207.
Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotrans-ferase levels. Ann Intern Med. 2002;137(1):1-10.
Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-1029.
doi: 10.1016/j.cgh.2010.08.026.
Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348-360.
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
Sansonno D, Tucci FA, Ghebrehiwet B, et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol. 2009;183(9):
-6020.
Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95(9):745-752.
Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and Non-Hodgkin Lymphoma: The Clinical Perspective. Hepatology. 2012;55(2):634-641.
Refbacks
- There are currently no refbacks.